

SeQuent Scientific receives EIR from US FDA for its Analytical Laboratory at Bengaluru

Thane, August 20, 2019: SeQuent Scientific Limited (SeQuent) announced that its wholly owned subsidiary SeQuent Research Limited (SRL) has received Establishment Inspection Report (EIR) from US FDA for its state-of-the-art GLP compliant, Analytical services laboratory at Bengaluru.

The Bengaluru laboratory was set up in 2017 to cater to the growing analytical requirements of large pharmaceutical and FMCG majors in the region. The facility is equipped with best-in-class infrastructure, strong team of trained analytical scientists and LIMS-enabled Quality Management System.

SRL also has another US FDA approved analytical laboratory at Mangaluru, which has been providing services since 2008. The Mangaluru laboratory was successfully inspected by the US FDA in December 2018.

About SeQuent Research Limited (SRL)

SRL is an ISO 17025 certified facility approved by major regulatory authorities including USFDA and operates out of two centers of excellence – Bengaluru and Mangaluru with a team of nearly 100 Scientists. It caters to the global pharmaceutical and FMCG industry in the areas of analytical method development, stability, microbiology testing and method validation of pharmaceutical and cosmeceutical products.

Both SRL centers are equipped with comprehensive capability in instrumental analysis, wet laboratory testing & trace element analysis and have LIMS conforming to 21 CFR.

About SeQuent Scientific Limited

SeQuent Scientific Limited (BSE-512529, NSE-SEQUENT) headquartered in Mumbai, India with a global footprint, operates in the domains of Animal Health (Alivira) and Analytical Services. SeQuent has eight manufacturing facilities based in India, Spain, Germany, Brazil and Turkey with approvals from global regulatory bodies including USFDA, EUGMP, WHO, TGA among others. Its Vizag facility is India's first and only USFDA approved facility for veterinary APIs.

For details, feel free to contact:

Tushar Mistry

Chief Financial Officer
Tel: +91 22 4111 4717
tushar.m@sequent.in

Diwakar Pingle

Christensen Investor Relations
Tel : +91 22 4215 0210
dpingle@christensenir.com

Abhishek Singhal

Investor Relations Consultants
abhishek.s@sequent.in

Registered Office

301/A, 'Dosti Pinnacle', Plot No. E7,
Road No. 22, Wagle Industrial Area,
Thane (W), Maharashtra, India
CIN: L99999MH1985PLC03668
BSE Code:512529 | NSE: SEQUEN
ISIN: INE807F01027 | REUTERS: EQU.BO
Websites: www.sequent.in

Certain statements in this document that are not historical facts are forward looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local, political or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. SeQuent Scientific Ltd. will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.